These impacts were partially offset by the changes in foreign currency rates, expiration of our U.S. and European Union commercialization rights to Abilify*, competitive pressures resulting from exclusivity losses and other factors for Baraclude, Reyataz and Sustiva in certain markets and the expiration/transfer of certain licensing and royalty rig
You should read the following discussion of our financial condition and results of operations in conjunction with our selected financial data, our financial statements, and the accompanying notes to those financial statements included elsewhere in this Annual Report on Form 10- K. This discussion contains forward-looking statements that involve ris
By a News Reporter-Staff News Editor at Health& Medicine Week Santalis Healthcare Corporation, a wholly owned subsidiary of TFS Corporation, Ltd., is pleased to announce that the first subject has been enrolled in a double-blind, placebo-controlled, randomized Phase 2 trial for the treatment of Molluscum contagiosum, testing a topical formulation
CIT Group Inc., cit.com, a leading provider of commercial lending and leasing services, today announced that CIT Healthcare Finance served as Lead Arranger for a $190 million senior secured credit facility to help finance the combination of Vertical/Trigen Holdings, LLC with Osmotica Holdings Corp Limited, a specialty pharmaceutical company with a.
Feb. 11 The experiment began with thousands of patient files, millions of prescription orders, billions of clinical measurements and a single question: Could big data be used to discover deadly drug combinations? For decades, scientists have wrestled with the problem that trusted prescription medications can combine in dangerous ways, often placi
LONDON Global branded and generic drugmaker Mylan NV has entered into a cash-and-stock deal to acquire specialty pharmaceutical company Meda AB for $9.9 billion including the Swedish company's net debt, ending a long pursuit to strike the deal. The deal comes three months after Mylan's failed hostile takeover of Perrigo Co., an Ireland- based drug
Feb. 10 Mylan said today it will acquire Swedish specialty pharmaceutical company Meda AB in a transaction valued at $9.9 billion. Mylan, which is based in the Netherlands but has its operational headquarters in Cecil, said the acquisition of Meda will broaden its product line and take it into China, Southeast Asia, Russia and other new markets.
-Cancer Diagnostic Testing World Markets.- Cardiac Marker Diagnostic Testing Markets.- Companion Diagnostics in Personalized Medicine and Cancer Therapy.- European Point of Care Diagnostic Testing Markets.- High-Growth Diagnostic Testing Markets.- Key Diagnostic Testing Markets.- Molecular Diagnostics in Cancer Testing.- Molecular Diagnostics in Ge
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors DUNGAN, Timothy; WARRINGTON, Brian, filed on May 29, 2015, was made available online on January 28, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Novartis AG. The follow
Feb. 09 GREENSBURG A call by local school administrators and teachers for changes in state-mandated standardized testing dominated discussion at a town hall-style meeting Saturday morning that brought two state senators and two House representatives to Greensburg for an update on the first half of the Indiana General Assembly's current legislat
Drugmaker Mylan says it will buy Meda AB of Sweden for $7.2 billion in cash and stock, and says the move will help it enter new markets. Mylan had $9.45 billion in revenue in 2015 and said Meda's revenue totaled about $2.35 billion. Mylan said the Meda deal will expand its over-the-counter drug business to about $1 billion in annual sales and wi
THREE AND NINE MONTHS ENDED DECEMBER 31, 2015. The following discussion and analysis should be read with the financial statements and accompanying notes included elsewhere in this Form 10- Q and in the Annual Report on Form 10- K for the year ended March 31, 2015. Without limiting the broader description of forward-looking statements above, we spec
Flamel Technologies today announced the acquisition of FSC Holdings, LLC, together with its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.. Mike Anderson, Chief Executive Officer of Flamel, stated, "FSC provides Flamel a commercial footprint into the US prescription pharmaceutical market with paten
The FDA said that since the government is still in process of how to monitor and regulate online sale of drugs, they cannot presently take action on people selling medicines online. We can not vouch for the quality of these medicines, "said BR Masal, FDA assistant commissioner, in the press release. All India Organisation of Chemists and Druggists